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PCN65
Real WoRld MaNageMeNt aNd Costs iN UNReseCtable MetastatiC 
MelaNoMa (MM) PatieNts: UPdate of a Pilot stUdy based oN aN 
iNstitUtioNal PatieNt RegistRy
Strens D.1, Specenier P.2, Peeters M.2
1Realidad, GRIMBERGEN, Belgium, 2University Hospital Antwerp, Edegem, Belgium
Objectives: To assess the management and associated lifetime costs in MM patients 
as from the diagnosis of unresectable metastatic disease until death. MethOds: A 
retrospective patient chart review was performed at the Antwerp University Hospital 
to obtain data on medical consumption related to the management of unresectable 
MM (uMM). A complete registry of all melanoma patients who visited the hospi-
tal between 2007 and May 2013 was compiled. Eligible for this retrospective chart 
review were patients with uMM with sufficient data available and who deceased 
before May 2013. Data on demographics, disease characteristics and management 
of uMM were collected. Direct costs were calculated by multiplying each item of 
resource use with its unit cost (2013, € ) using the Belgian public health care payer’s 
perspective (PHCP) and patient’s perspective. Average (bootstrap 95%CI) overall costs 
per patient were calculated. Results: Out of 338 registered melanoma patients, 
35 were eligible and included in this chart review. The median overall survival time 
(OS) in all patients was 6.2 months. 88.6% (n= 31) of patients were treated by sys-
temic treatment(s) of which 17% (n= 6) received up to 4 different treatment lines. 
Ten patients received “new drugs”: ipilimumab (1 to 4 cycles): 10; vemurafenib: 2. 
Fifty-six (41%) of the 137 hospitalizations were for treatment administration. The 
mean overall cost per patient was € 43,429 (bootstrap 95% CI: 33,372 - 54,351), of 
which € 42,367 (95%CI: 32,481 - 52,976) was reimbursed. The PHCP cost was driven 
by systemic treatments costs (46% of cost). Mean PHCP cost was € 87,468 (95 % CI: 
77,372-97,307) for patients treated with “new drugs” versus € 24,327 (95 % CI: 18,617 - 
30,634) for patients not treated with “new drugs”. Median OS was 9 and 4.9 months, 
respectively. cOnclusiOns: Management of uMM results in considerable costs for 
the PHCP, mainly driven by systemic treatment costs.
PCN66
MaNageMeNt Costs of the fiRst five yeaRs afteR diagNosis iN bReast 
CaNCeR by stage iN fRaNCe
Atsou K.1, Bardoulat I.1, Colin X.1, Lemasson H.1, Ricarte C.2, Maurel F.2, Ajjouri R.3, Lançon F.3
1IMS Health, La Défense Cedex, France, 2IMS Health, La Défense, France, 3Institut National du 
Cancer, Boulogne Billancourt cedex, France
Objectives: Few recent data are available on breast cancer treatment costs, espe-
cially by stage of the disease at diagnosis. This study was designed to estimate the 
management costs in breast cancer for the first 5-year period following diagno-
sis. Costs have been distinguished by stage of severity. MethOds: A patient-level 
analysis was performed from a French physician survey database, collecting data 
on patient demographics, cancer history from diagnosis and treatment patterns. 
Data were extracted for all breast cancer cases with at least 1 year of follow-up after 
diagnosis using data collected from 2011 to 2012. Cost analyses were conducted 
from a health care payers’ perspective adjusting for stage (stages I-IV) at diagnosis 
and year from diagnosis. Results: A total of 1,157 patients were included in the 
analysis. The stages at diagnosis distribution was respectively from stage I to IV 
29.7%, 39.2%, 15.0% and 16.1%. The mean (SD) age at inclusion was 62.5 (12.4) and 
the mean (SD) time from diagnosis was 5.0 years (5.1). The mean annual cost (SD) 
over the 5-year period after diagnosis was ranging from 4,293€ (9,526€ ) for stage I 
to 12,111€ (19,070€ ) for stage IV. The mean (SD) annual costs for the 1st year after 
diagnosis were estimated at 11,647€ (9,883€ ), 13,226€ (11,575€ ), 17,254€ (14,535€ ) 
and 24,003€ (24,888€ ), respectively for stage I to IV at diagnosis. The main cost con-
tributors in early stages were radiotherapy and surgery while cytotoxic treatments, 
hormonotherapy and supportive care droved it for the late stage. The mean annual 
costs for the following years after diagnosis (2nd to 5thyear) decreased, ranging from 
1,827€ (8,964€ ) for Stage I to 5,370€ (10,662€ ) for stage IV. cOnclusiOns: : The mean 
annual cost was strongly related to the clinical stage at diagnosis and the year from 
diagnosis. These estimates could be useful to populate models that explore impact 
of treating and preventing breast cancer.
PCN67
the hUMaNistiC aNd eCoNoMiC bURdeN of veNoUs thRoMboeMbolisM 
iN CaNCeR PatieNts: a systeMatiC RevieW
Kourlaba G.1, Relakis J.2, Kontodimas S.3, Holm M.V.4, Maniadakis N.2
1National and Kapodistrian University of Athens School of Medicine, Athens, Greece, 2National 
School of Public Health, Athens, Greece, 3LEO Pharmaceutical Hellas S.A., Athens, Greece, 4LEO 
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Objectives: To systematically review the humanistic and economic burden of 
cancer-related venous thromboembolism (VTE). MethOds: A literature search 
was carried out on Pubmed, Cochrane Central Register of Controlled Trials, Econlit, 
Science Direct, JSTOR, Oxford Journals and Cambridge Journals. The search was 
limited to humanistic studies published from January 2000 to December 2012. 
Additional studies were also identified by searching reference lists of relevant 
published reviews and included studies. The identified studies were indepen-
dently reviewed by two reviewers against pre-determined inclusion and exclu-
sion criteria. A quality assessment of the selected studies was also conducted by 
using standard methods . The data of selected studies were extracted onto a data 
extraction form and consequently synthesized. Results: Fifty five studies were 
included in our review. It was found that cancer patients experience between 
2-fold and 20-fold higher risk of developing VTE in comparison to non-cancer 
patients. Cancer patients are more likely to experience a VTE event in the first 3 
or 6 months after cancer diagnosis and the onset of chemotherapy. Additionally, 
an increased risk of VTE in patients with distant metastases and certain types of 
cancer (i.e. pancreatic or lung) was identified. VTE strongly affects the prognosis 
of cancer patients as it has been found that it is a leading cause of death in this 
group of patients. The annual average total cost for cancer patients with VTE was 
found to be almost 50% higher compared to that of cancer patients without VTE 
nities through the utilization of allied health professionals. MethOds: Two local 
CPHHD programs with prospective randomized controlled trial designs (a virtual 
team care intervention aimed at reducing depressive symptoms in older adults 
with depression and cardio-metabolic syndrome, and a patient navigator program 
to increase mammography screening for breast cancer) provided the underlying 
data for this analysis. The programs collected detailed resource use data along 
with several clinical measures. Costs were measured from a payer perspective. 
The navigator program involved in-person or remote navigator consultations, and 
costs were based on a wage rate of $15 per hour. The depression program involved 
multiple services and all costs reflected institution-specific billing data. Results: 
There were 949 patients in the patient navigator intervention. On average, these 
patients received 8.28 minutes of navigator services per patient over the phone and 
1.23 minutes via in-person visits, translating to a per-patient cost of $2.38. For the 
six patients enrolled in the team care intervention for depression, resources used 
included social worker case management and individual psychotherapy, translating 
to program costs of $145 per patient over 12 months. Spillover health care service 
costs were similar between the intervention and control groups (intervention = 
$55 per patient, control = $64 per patient). cOnclusiOns: Costs are an important 
consideration for evaluating pilot, team-care based interventions to improve patient 
health. The two programs evaluated here offer insight into the potential impact of 
interventions that employ allied health professionals and demonstrate a relatively 
low cost per patient. Future work will examine these costs in comparison with 
measured effects of the program.
PCN63
assessiNg the bURdeN of CaRegiviNg foR PatieNts With lUNg CaNCeR 
iN eURoPe
Goren A.1, Gilloteau I.2, Penrod J.R.2, Jassem J.3
1Kantar Health, New York, NY, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Medical 
University of Gdansk, Gdansk, Poland
Objectives: To investigate the self-reported burden imposed by care of lung 
cancer (LC) patients in the European Union (EU). MethOds: The study included 
respondents to the 2010 and 2011 EU National Health and Wellness Survey from 
France, Germany, Italy, Spain, and the UK who reported being caregivers for a rela-
tive with LC versus respondents who did not report being caregivers for a relative 
with any condition (control). Outcome measures included Short Form (SF)-6D 
health state utilities and mental and physical health status (all derived from the 
SF-12v2), stress-related comorbidities, health care resource use during the past 
6 months, and work/activity impairment during the past week using the Work 
Productivity and Activity Impairment (WPAI) questionnaire. Productivity losses 
were converted into costs using the human capital method by applying median 
hourly wages per country (from Eurostat 2006 personal income inflated to 2010) 
to the total number of hours lost using results from WPAI. Multivariable analyses 
were used to test the potential impact of LC patient caregiving on health care 
resource use and work/activity impairment, as well as costs specifically associated 
with work impairment. Results: A total of 107 caregivers for patients with LC and 
103,868 non-caregivers were identified. Compared with non-caregivers and adjust-
ing for covariates, caregivers had higher mean levels of impaired presenteeism 
(27.1% vs. 14.8%), overall work impairment (32.4% vs. 18.0%), and activity impair-
ment (32.8% vs. 21.8%; all p< 0.005); higher odds of impact across all measures 
of the WPAI including absenteeism (all p< 0.01); and higher annual costs associ-
ated with impaired presenteeism (€ 5,672 vs. € 3,429) and overall work impairment 
(€ 6,905 vs. € 4,147; both p< 0.05). Health care resource utilization and mean level 
of absenteeism did not differ significantly. cOnclusiOns: LC patient caregiving 
in the EU is associated with significantly higher work/activity impairment and 
related costs relative to non-caregivers. Costs associated with LC caregiver burden 
deserve further attention.
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diReCt MediCal Costs (dMC) of tReatiNg ChRoNiC lyMPhoid leUkeMia 
(Cll) PatieNts iN the PUbliC health CaRe systeM iN bRazil: ResUlts 
fRoM a RetRosPeCtive aNalysis of aN adMiNistRative database
Asano E., Pereira M.L.
Janssen-Cilag Farmaceutica, Sao Paulo, Brazil
Objectives: To determine direct medical costs of treating patients with Chronic 
Lymphoid Leukemia (CLL) from the Brazilian Public Healthcare System perspec-
tive. MethOds: A retrospective longitudinal analysis of the Government admin-
istrative claims database (Datasus) was performed. Eligibility criteria were patients 
starting CLL (ICD-10 code C911) chemotherapy from Jan/2008 to Dec/2011, with 
complete information and no inconsistency in date of birth, gender. Outpatient 
and inpatient databases were combined through deterministic linkage. Outcome 
was direct medical costs (DMC), calculated as the sum of the medical claims for 
each patient included in the analysis, for a maximum period of 5 years or death or 
loss of follow-up, whichever comes first. DMC was categorized in chemotherapy, 
hospitalizations, and other outpatient costs. Results: From 5100 patients with CLL 
identified in the database, 613 met eligibility criteria. Median follow-up time was 25 
months. This population cohort had 54% males with average age at start of treat-
ment of 66.4 ± 11.7 years. Patients received an average of 12.0 ± 9.4 months of chemo-
therapy treatment, with 71% of them treated by one type of chemotherapy regimen. 
Total DMC in this population was R$ 7,021,631.48 (average cost of R$ 6,404.52 ± 
6,133.37 per patient-year), from which R$ 5,384,552.12 (77%) are related to chemo-
therapy, R$ 1,062,978.98 (15%) to hospitalizations and R$ 574,100.38 (8%) to other 
outpatient costs. Outpatient laboratory exams accounted for 6% (R$ 397,050.07) of 
total DMC. 30 (5%) patients underwent radiotherapy treatment, with total costs of 
R$ 53,944.96 (< 1% of DMC). A total of 862 hospitalizations were identified in 287 
(46.8%) patients, with an average cost of R$ 1,233.15 ± 3,879.86 per hospitaliza-
tion. cOnclusiOns: Patients with CLL represent a significant economic burden 
to the public health system. Chemotherapy and hospitalization costs accounts for 
more than 90% of the total costs.
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platinum-based agents 20.3%, UFUR 8.3%, taxanes 7.7%, etoposide 7.5%). Close to 
three quarters (74.8%) of treated patients received combination therapy with plat-
inum-based agents. Of 1,221 patients treated with platinum-based combination 
therapy, the therapy most commonly used includes gemcitabine (37.5%), taxanes 
(21.5%), and vinorelbine (18.2%), while 21.4% of patients received two or more other 
agents. We observed longer median survival in patients with a higher number of 
chemotherapy agents received. cOnclusiOns: Lung cancer patients in Taiwan 
incurred considerable health care costs after diagnosis. More than half of patients 
were treated with chemotherapy, in particular with multiple chemotherapy agents. 
Future research comparing cost-effectiveness among different treatment options 
is warranted.
PCN71
aUstRaliaN staNdaRd Costs aNd CoNseqUeNCes of foUR 
CheMotheRaPy adveRse eveNts
Pearce A.M., Haas M., Viney R.
University of Technology, Sydney, Ultimo, Australia
Objectives: This work aimed to develop rigorous models of the Australian costs of 
four common chemotherapy adverse event (diarrhoea, vomiting, anaemia and neu-
tropenia), which provide standard cost estimates and can be used in future models 
of chemotherapy cost effectiveness. MethOds: Decision analytic modelling was 
used to identify the costs and consequences of AEs. These are not only stand alone 
models, but also form decision tree sections to be incorporated into larger models 
of chemotherapy cost effectiveness. Model structures are based on best-practice 
clinical pathways, and incorporate efficacy of side effect treatment, quality of life 
and chemotherapy dose. Literature reviews identified clinical inputs. Costs of treat-
ment were obtained from standard Australian sources such as the Pharmaceutical 
Benefits Schedule. The perspective was the Australian health care system. One-way 
sensitivity analyses explored uncertainty in the models. Results: The base case 
average cost per patient of diarrhoea ranged from $19 (mild AE) to $4,821 (severe AE); 
those for anaemia ranged from $51 (mild AE) to $17,100 (moderate AE) depending on 
the type of chemotherapy and anaemia treatment. Vomiting prevention base case 
costs ranged from $0.84 (low risk chemotherapy) to $157.55 (high risk chemotherapy 
requiring breakthrough and refractory management). Neutropenia base case costs 
ranged from $2,235 (outpatient management) to $12,054 (intensive care required). 
Where possible, the impact on quality of life and chemotherapy total dose was also 
modelled. Estimates of AE costs vary widely in the literature, however our estimates 
appear consistent with studies of similar methodology. cOnclusiOns: The four 
models presented represent best-practice modelling techniques for chemotherapy 
AEs. Each has been designed to enable either the results or the model structure to 
be incorporated into larger models of chemotherapy cost effectiveness. This allows 
model builders to incorporate rigorous, Australian-specific estimates of the costs and 
consequences of chemotherapy AEs into models of chemotherapy cost effectiveness.
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hoRMoNal ReCePtoR Positive, heR2 Negative MetastatiC bReast 
CaNCeR (MbC hR+heR2-): PRe aNd Post-PRogRessioN Costs UNdeR the 
PUbliC health CaRe systeM (sUs) aNd soCietal PeRsPeCtives iN bRazil
Haas L.C.1, Fernandes R.A.1, Bines J.2, Caldas A.3, Valentim J.3
1ANOVA, Rio de Janeiro, Brazil, 2Clementino Fraga Filho Hospital, Federal University of Rio de 
Janeiro, Rio de Janeiro, Brazil, 3Novartis Biociências SA, São Paulo, Brazil
Objectives: To estimate direct medical costs and productivity costs of hormonal 
receptor positive, HER2 negative metastatic breast cancer (MBC HR+ HER2-) under 
the public health care system (SUS) and societal perspectives in Brazil, being MBC 
cost data very scarce in Brazil so far. MethOds: A systematic literature review was 
performed in the following databases: Cochrane, MEDLINE via Pubmed, LILACS, 
EMBASE and CRD until FEB 2013. Gray literature was also included. National guide-
lines search and expert validation was carried out specifically for the direct medical 
cost estimations. Direct medical costs were stratified as pre and post-progression 
costs and terminal costs. Pre and post-progression costs considered outpatient, 
inpatient and monitoring costs. For post-progression, metastasis treatment costs 
were also estimated, including bone, lung, liver and brain metastasis. For the pro-
ductivity costs, the Human Capital method was chosen. Days of absenteeism were 
obtained from the literature and a Markov model was used to estimate the loss of 
productivity in 1 year (as the mean age of MBC in Brazil is 59 and official retirement 
at 60 years of age). Unit costs were obtained from Brazilian official lists and IBGE 
(income). All costs are expressed in 2012 Brazilian Real (BRL). Results: Pre, post-
progression and terminal costs of MBC HR+HER2-were estimated in BRL308, BRL731 
and BRL4.164 respectively, under SUS perspective. Post-progression metastasis treat-
ment costs presented an average of BRL12.047 under SUS perspective. The productiv-
ity costs were estimated in BRL26.056 under the societal perspective considering 
the available treatments at SUS for MBC HR+HER2- patients. cOnclusiOns: MBC 
HR+HER2- post-progression costs impose a significant economic burden under SUS 
perspective as well as productivity losses to the society. Novel therapies that post-
pone progression in those patients may reduce costs associated.
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estiMatiNg the Cost of hPv-Related diseases iN tURkey: a delPhi 
aPPRoaCh
Bakir M.1, Ayhan A.2, Arvas M.3, Kose M.F.4, Gungor M.5, Ortac F.6, Ozgul N.7, Yuce K.7, Ergun T.1, 
Gungor E.5, Altundag O.2, Saka G.8
1Marmara University School of Medicine, Istanbul, Turkey, 2Baskent University School of Medicine, 
Ankara, Turkey, 3Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey, 4Bahcesehir 
University School of Medicine, Istanbul, Turkey, 5Acibadem University School of Medicine, Istanbul, 
Turkey, 6Ankara University School of Medicine, Ankara, Turkey, 7Hacettepe University School of 
Medicine, Ankara, Turkey, 8Merck Sharp Dohme, Istanbul, Turkey
Objectives: Very limited data is available on the cost and burden of HPV-related 
diseases in Turkey. The aim of our analysis is to evaluate the corresponding cost 
through understanding the current clinical practices, use of resources and treat-
in the USA in 2002. Inpatient care costs accounted for more than 60% of total 
cost. cOnclusiOns: Although the economic impact of the VTE in cancer patients 
as well as the impact of VTE on patients’ quality of life is not well studied, the 
present review demonstrate that there is a substantial humanistic and economic 
burden associated with VTE in cancer patients.
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a MiCRo-CostiNg of the iNPatieNt MaNageMeNt of febRile 
NeUtRoPeNia iN the iRish health CaRe settiNg
McCullagh L.1, O’Brien C.2, Fogarty E.1, Walsh C.3, Dempsey O.3, Barry M.1, Kennedy M.J.2
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2St James’s Hospital, Dublin, Ireland, 
3Trinity College Dublin, Dublin, Ireland
Objectives: Febrile neutropenia (FN) is a potentially life-threatening complica-
tion of chemotherapy which generally prompts immediate hospitalisation. The 
study objective was to evaluate the resource use and cost of hospitalisation for 
FN within the Irish Health care setting. Micro-costing techniques were used. The 
health payer perspective was adopted. MethOds: This was a single centre study. 
Adult cancer patients undergoing chemotherapy, who were subsequently admit-
ted for FN, were identified prospectively. Patient medical records were reviewed 
retrospectively. Results: Patient demographics and resource utilisation data (per-
taining to the management of FN) were obtained from a cohort of 32 patients (69% 
female, mean age = 58.8 years). Twenty-five percent of patients had more than one 
FN episode. In total, 42 FN episodes were captured; 60% of episodes had occurred 
within the first two cycles of chemotherapy. The bootstrap estimation was used to 
determine mean hospital length of stay (LOS) with standard deviation (± SD) and 
mean costs (± SD). The mean LOS was 7.3 (± 0.5) days. The mean cost per FN episode 
was € 8,915 (± 718). The major cost driver was hospital bed-stay (mean cost of € 6,851 
(± 549)). Other cost drivers included antibacterial treatment at € 760 (± 156), labora-
tory investigations at € 538 (± 47) and the requirement for blood bank products at 
€ 525 (± 189). cOnclusiOns: To our knowledge, this is the first investigation of the 
cost of chemotherapy induced FN within the context of the Irish Health care setting. 
Our results will be used in cost-effectiveness analyses of novel chemotherapeutic 
agents and interventions which prevent or treat FN.
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the Cost of NsClC iN fRaNCe
Martin M.1, Mcguire A.2, Marty R.3, Lenz C.4
1OptumInsight, Uxbridge, Middlesex, UK, 2London School of Economics, London, UK, 3HEVA HEOR, 
Lyon, France, 4Pfizer, Berlin, Germany
Though lung cancer, and the most common subtype, non-small cell lung cancer 
(NSCLC), occur frequently, there are limited data quantifying the economic burden 
of these cancers in Europe.Objectives: To describe the burden of NSCLC in three 
European countries using patient-level data from commercially available health 
care data. MethOds: Patient-level data were obtained for France from the PMSI 
(French National discharge database; containing data from publicly-funded hos-
pitals) from 2008 to 2011 while excluding patients with a prior-hospitalization for 
lung cancer in the preceding 24-month period (2006-2007). As NSCLC does not have 
a separate ICD-10 code, expert opinion was used to eliminate patients diagnosed 
with non-NSCLC, based on particular procedures and tests. Hospital resource 
use was valued using French DRG tariffs. Chemotherapy regimens were valued 
using official rates. Results: A total of 61,144 patients were identified with lung 
cancer in 2008. 19,099 were excluded because of prior lung cancer diagnoses. Of 
this cohort of 42,043 patients, 25,054 were exclusively treated in the public setting; 
15,061 were identified as NSCLC and were considered in this analysis. Hospital-
related costs cumulated over the follow-up period were estimated at € 337,382m, 
with chemotherapy costs representing 9%. Mean cumulated hospital-related 
cost per-patient were estimated at € 22,401 over the follow-up period. Terminal 
care represented a mean per-patient cost of € 10,440. Adverse events triggering 
hospital-expenses represented a mean per-patient cost of € 5,694. Patients ≤ 55 
years incurred higher costs per-person over the follow-up period than patients > 55 
years; € 25,386 vs. € 21,368. These extra costs were mostly driven by chemotherapy 
costs(€ 13,287 vs. € 10,561). Patient with metastases incurred higher costs over the 
follow-up period than patients without these, € 23,118 vs. € 21,934. cOnclusiOns: 
This is one of the first analyses quantifying the economic burden of NSCLC. The 
burden for France is substantial. Subsequent analyses will allow for comparisons 
of this burden across other countries.
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CheMotheRaPy tReatMeNt PatteRNs, health CaRe Costs, aNd 
MoRtality of lUNg CaNCeR PatieNts iN taiWaN – a loNgitUdiNal 
stUdy betWeeN 2000 aNd 2008
Liang F.W.1, Chen S.Y2, Tsai C.F.1, Jen M.H.3, Li C.Y.1, Wasiak R.3, Boulanger L.2, Lu T.H.1
1National Cheng Kung University, Tainan City, Taiwan, 2Evidera, Lexington, MA, USA, 3Evidera, 
London, UK
Objectives: To examine chemotherapy treatment patterns, health care costs, 
and mortality of lung cancer patients in Taiwan. MethOds: This study analyzed 
medical and pharmacy claims from a random sample of one million taken from 
all beneficiaries covered under Taiwan’s national health insurance in 2000. Newly 
diagnosed lung cancer patients between 2000 and 2008 (first observed diagnosis as 
the index date) were identified based on medical claims with associated diagnoses. 
Patients were followed until death or the end of 2008. Per patient per month [PPPM] 
total health care costs (in USD) and median survival were reported. Chemotherapy 
treatment patterns during the follow-up were examined. Results: This study 
included 3,343 lung cancer patients (mean age: 67.1 years; 34.5% female; 35.4% 
secondary lung cancer). Median survival was 8.1 months. PPPM costs were $2,322 
USD (interquartile range $450-$2,902). Lifetime costs from diagnosis among those 
who died during the study period were $12,788 USD (interquartile range $2,674-
$17,546). Of the 1,633 patients who received chemotherapy during the follow-up, 
375 received only one chemotherapy agent (gemcitabine 35.7%, vinorelbine 20.5%, 
